Moreover, each CIC subtype tended to preferentially affect different categories of breast cancer, with TiT (<i>P</i> < 0.0001) and oCICs (<i>P</i> = 0.008) targeting luminal B (Her2<sup>+</sup>), TiM (<i>P</i> = 0.011) targeting HR<sup>-</sup> (Her2<sup>+</sup>/HR<sup>-</sup> and TNBC), and MiT targeting luminal A (<i>P</i> = 0.017) and luminal B (Her<sup>-</sup>) (<i>P</i> = 0.006).
In contrast, breast cancer CD44(+)/CD24(-/low) CIC have dysregulated innate immune responses featuring dysfunctional virus recognition caused by impaired trafficking of TLR9 and cofactor MyD88 and the absence of TLR2, having a deleterious impact on TLR pattern recognition receptor signaling.